Therapeutics News and Research

RSS

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE).

11 Nov 2010

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Capstone Therapeutics, formerly OrthoLogic Corp.,, today announced financial results for the third quarter of 2010.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics plc announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.

10 Nov 2010

Albert Einstein researcher receives Medal of Honor from American Cancer Society

Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

10 Nov 2010

Iris BioTechnologies awarded $245,000 grant under QTDP Program

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, is pleased to announce that the company has been awarded $245,000, the maximum amount given for a grant under the US Qualifying Therapeutic Discovery Project (QTDP) Program.

10 Nov 2010

NeoPharm, Insys complete merger

NeoPharm, Inc., a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has completed its merger with Insys Therapeutics, Inc., a Phoenix, AZ based pharmaceutical company.

10 Nov 2010

EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076. Data for the ENMD-2076 Phase 1 studies in multiple myeloma and leukemia will be presented by EntreMed investigators at the 2010 Annual Meeting of the American Society of Hematology (ASH) to be held December 4-7 at the Orange County Convention Center in Orlando, Florida.

9 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

New approach to treat castration resistant prostate cancer

9 Nov 2010

Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.

9 Nov 2010

Fabrus, Ambrx commence joint research program for antibody drug conjugates

FABRUS, LLC announces that the Company and San Diego-based Ambrx Inc. have commenced a joint research program to discover antibodies with properties that are optimized for use as antibody drug conjugates.

9 Nov 2010